Incyte Corporation - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
INCY Nasdaq 8731 http://www.incyte.com 113.71 Stock Down -1.16

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Incyte Corporation

See what the IHS Markit Score report has to say about Incyte Corp. - Sep 20th, 2017 6:01 am
Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress - Sep 19th, 2017 2:05 pm
Incyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell - Sep 18th, 2017 8:00 am
Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study - Sep 15th, 2017 7:51 am
Lilly/Incyte pill beats placebo in mid-stage eczema trial - Sep 14th, 2017 12:49 pm
Have Investors Already Priced In Incyte Corporation’s (INCY) Growth? - Sep 14th, 2017 11:19 am
Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis - Sep 14th, 2017 7:00 am
ETFs with exposure to Incyte Corp. : September 13, 2017 - Sep 13th, 2017 4:39 pm
This Analyst Predicts Bullish Growth Outlook For Incyte - Sep 12th, 2017 7:28 am
Incyte Corp. :INCY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 - Sep 11th, 2017 12:30 pm
Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : September 11, 2017 - Sep 11th, 2017 8:44 am
[$$] AstraZeneca, Merck and Inctye boosted by cancer treatment advances - Sep 11th, 2017 8:21 am
Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma - Sep 9th, 2017 6:49 am
Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma - Sep 9th, 2017 6:45 am
Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers - Sep 8th, 2017 8:39 am
Incyte Announces Pricing of Public Offering of 4,945,000 Shares of Common Stock - Sep 8th, 2017 6:35 am
Incyte Announces Proposed Public Offering of 4,945,000 Shares of Common Stock - Sep 7th, 2017 3:28 pm
Alexion: Quite a Comeback - Sep 5th, 2017 9:50 am
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August - Sep 5th, 2017 8:46 am